FDA Grants Priority Review to KEYTRUDA + Concurrent ChemoRT as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer October 11, 2023
FDA Grants Priority Review to KEYTRUDA + Concurrent ChemoRT as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer September 26, 2023
TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved OS in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy September 13, 2023
Ph 3 KEYNOTE-A18 Trial Met Primary Endpoint of PFS in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer July 27, 2023
Positive final results from Ph 2 trial of VB10.16 + atezolizumab in advanced cervical cancer announced April 27, 2023
Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer February 22, 2023
100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Ph 2 Trial announced November 23, 2022
Additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer announced November 16, 2022
Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer presented September 13, 2022
